Photo taken from: Mark Lewis/X
Feb 14, 2024, 18:02
Mark Lewis: Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!
Mark Lewis shared on X:
“Seems relevant to resurface Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!”
Source: Mark Lewis/X
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27